Printer Friendly

Cardiovascular risk biomarkers not yet ready for clinical use.

SAN FRANCISCO -- None of the newer biomarkers being evaluated as possible predictors of cardiovascular risk have been studied enough to be considered ready for clinical use, Michael H. Alderman, M.D., said at the annual meeting of the American Society of Hypertension.

Conventional risk factors such as blood pressure, insulin resistance, diabetes, obesity, lipids, and family history account for 50% of cardiovascular risk, so any biomarkers that could further gauge risk would be useful. A biomarker is a substance that can be measured precisely in serum or urine and is related to subsequent occurrence of cardiovascular disease--such as cholesterol, said Dr. Alderman of Albert Einstein College of Medicine, New York.

A handful of newer, more precise biomarkers appear to be more intimately associated with the development of cardiovascular disease and look like they will be useful. These include C-reactive protein, neurocytokines, and uric acid. So far, however, there is "suggestive, but for the most part not yet convincing, evidence that these new biomarkers add to the predictive value already contained in the markers that we have," Dr. Alderman said at a press briefing during the meeting, where he gave a summary of reports on the newer biomarkers.

To be useful, a new risk marker would have to make a contribution beyond what's obtained from conventional risk markers. "I don't think that's been formally tested" with the newer biomarkers, he said.

Tests for the new risk marker would have to be reproducible at different times and in different populations, and would have to define an important amount, or proportion, of risk. Lastly, an assay for the biomarker would need to be feasible and cost effective when applied to a population.

"Those kinds of questions have been asked of blood pressure screening and cholesterol screening, but haven't been asked of cytokines," for example, he said.

Dr. Alderman said he believes that uric acid is an independent risk factor for cardiovascular events, particularly in hypertensive patients, but the data supporting this are inconsistent. Other data showing that uric acid is predictive of elevated blood pressure may be more interesting and useful, he said.


San Francisco Bureau
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Cardiovascular Medicine
Author:Boschert, Sherry
Publication:Internal Medicine News
Geographic Code:1USA
Date:Aug 15, 2005
Previous Article:Carotid wall thickness, coronary calcium both predictive in elderly.
Next Article:HPV cotesting policy slow to gain acceptance: Kaiser officials expected a 'tidal wave of specimens' with Pap smears, but staff training was a key...

Related Articles
C-Reactive protein testing endorsed for limited use: CRP assay not for population screening, American Heart Association, CDC say. (When 10-Year Risk...
Four biomarkers predict cardiovascular events in women.
FDA panel urges review of CV risks of diabetes drugs; Long-term safety studies recommended.
Symposium highlights cardiovascular disease prevention.
Lipoprotein-associated phospholipase A2: A risk marker or a risk factor?
Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Biomarkers' ability to improve prediction of heart risk minimal, say experts.
Proteomic and Genomic Analysis of Cardiovascular Disease.
Biomarkers don't predict cardiovascular events.
Combination of biomarkers may improve diagnosis, management of heart failure.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters